Patrick Burnett sold $921k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 61,403 shares at an average of $14.99, traded Mar 13, 2025, filed Mar 17, 2025.
Score components
- +15RoleOfficer
- +24Trade size$921k at market
- +10Share of holdings soldSold 37% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-25-000045, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -44,153 | $14.97 | $661k | 121,936 | Mar 17, 2025 |
| Mar 13, 2025 | MOption exercise Common Stock10b5-1 | +5,008 | $0.00 | $0 | 126,944 | Mar 17, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -5,008 | $15.10 | $76k | 121,936 | Mar 17, 2025 |
| Mar 14, 2025 | MOption exercise Common Stock10b5-1 | +12,242 | $0.00 | $0 | 134,178 | Mar 17, 2025 |
| Mar 14, 2025 | SOpen-market sale Common Stock10b5-1 | -12,242 | $15.04 | $184k | 121,936 | Mar 17, 2025 |
| Mar 13, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,008 | $0.00 | $0 | 213,492 | Mar 17, 2025 |
| Mar 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -12,242 | $0.00 | $0 | 201,250 | Mar 17, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 22Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $178k 10,129 shares | -1% | |
| 34Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $584k 36,130 shares | -18% | |
| 6Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $156k 10,000 shares | -9% | |
| 11Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $66k 4,188 shares | -4% | |
| 17Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $54k 3,847 shares | -3% | |
| 6Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $143k 10,000 shares | -9% | |
| 19Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $91k 6,330 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.